AGP Executive Report
Last update: 7 hours agoFDA Approvals: The FDA approved Takeda’s oveporexton (Orzeyful) for adult narcolepsy type 1, and also granted RMAT status to Aspen Neuroscience’s sasineprocel (ANPD001), signaling momentum in orexin-targeting sleep and spinal muscular atrophy research. Brain Health & Supplements: A new review pushes back on hype around creatine as a brain-health “nootropic,” saying the science is biologically plausible but still early and mixed for healthy adults. Behavioral Health Access: Colorado’s Paragon Behavioral Health opened a 24/7, low-barrier walk-in crisis center designed to meet people where they are, including substance-use and suicidality crises. Healthcare Business: RadNet reported record Q2 revenue and raised 2026 guidance, while UnitedHealth pledged $4M to expand Tennessee’s health hub network to 13 sites by 2027. Public Health & Prevention: Westmoreland urged Hepatitis B vaccination and safer sex, and a Lancet Global Health analysis highlights how low birth-dose coverage keeps mother-to-child HepB transmission high in parts of Africa. Health Tech & Investment: Egypt is exploring a specialized biotech and health-tech investment fund, aiming to bridge research to market and boost local manufacturing. Regulatory/Compliance: Maharashtra’s FDA announced a one-year ban on analogue paneer amid health complaints, as enforcement actions expand. Emergency Demand: New Zealand’s St John reported sustained record ambulance call volumes, with guidance to call 111 again if conditions worsen.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
